The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Ardelyx, Inc.

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

When you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to debate your rights freed from charge. You can too reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com

The category, on this case, has not yet been certified, and until certification occurs, you aren’t represented by an attorney. When you decide to take no motion, you’ll be able to remain an absent class member.

In accordance with the Grievance, the Company made false and misleading statements to the market. Ardelyx touted its future revenue potential the industrial success of its XPHOZAH phosphorus inhibitor. The Company claimed it was attempting to incorporate XPHOZAH within the Transitional Drug Add-on Payment Adjustment program ("TDAPA"). In point of fact, the Company had not made a firm decision on whether it could apply to incorporate XPHOZAH within the TDAPA.

The Schall Law Firm represents investors all over the world and makes a speciality of securities class motion lawsuits and shareholder rights litigation.

This press release could also be considered Attorney Promoting in some jurisdictions under the applicable law and rules of ethics.

View the original press release on accesswire.com

COMTEX_458737854/2457/2024-10-12T11:10:29